BPTS vs. VRPX, CING, EVOK, KTRA, THAR, MBIO, ZVSA, PCSA, GNPX, and NEXI
Should you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Virpax Pharmaceuticals (VRPX), Cingulate (CING), Evoke Pharma (EVOK), Kintara Therapeutics (KTRA), Tharimmune (THAR), Mustang Bio (MBIO), ZyVersa Therapeutics (ZVSA), Processa Pharmaceuticals (PCSA), Genprex (GNPX), and NexImmune (NEXI). These companies are all part of the "pharmaceutical preparations" industry.
Virpax Pharmaceuticals (NASDAQ:VRPX) and Biophytis (NASDAQ:BPTS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
Virpax Pharmaceuticals' return on equity of 0.00% beat Biophytis' return on equity.
32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 6.2% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Biophytis received 4 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users.
In the previous week, Biophytis had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Biophytis and 0 mentions for Virpax Pharmaceuticals. Virpax Pharmaceuticals' average media sentiment score of 0.17 beat Biophytis' score of 0.00 indicating that Biophytis is being referred to more favorably in the news media.
Biophytis has a consensus target price of $600.00, indicating a potential upside of 5,797.85%. Given Virpax Pharmaceuticals' higher probable upside, analysts clearly believe Biophytis is more favorable than Virpax Pharmaceuticals.
Virpax Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Biophytis has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.
Summary
Biophytis beats Virpax Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Get Biophytis News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biophytis Competitors List
Related Companies and Tools
